Vion falls on Onrigin complete response

Vion Pharmaceuticals Inc. (OTCBB:VION) fell $0.17 (22%) to $0.62 on Monday after FDA requested the company complete a randomized study in a complete response letter for an NDA for Onrigin laromustine. Vion was seeking accelerated approval of Onrigin as a single agent for remission induction in patients ages 60 and up with de novo, poor-risk acute myelogenous leukemia (AML). The company had previously said that it does not have enough funds for a new randomized study and if it is not successful in completing a sale of assets, restructuring or financing, it will have to curtail or cease operations, liquidate its assets or file for bankruptcy. ...